Screening test for recognizing prostate diseases and apparatus and diagnosis substance for carrying out the test

• US 8,386,012 B2
• Filed: 07/31/2008
• Issued: 02/26/2013
• Est. Priority Date: 08/03/2007
• Status: Expired due to Fees

• Current Assignee: Siemens Healthcare GMBH (Siemens AG)
• Original Assignee: Siemens AG
• Inventors: Fehre, Jens, Nanke, Ralf, Stetter, Martin
• Primary Examiner(s): Smith, Ruth S
• Application Number:
  US12/671,643
• Publication Number:
  US 20110230752A1
• Time in Patent Office: 1,671 Days
• Field of Search: 600/409, 600/431, 424 93- 937, 424/648
• US Class Current: 600/409
• CPC Class Codes: A61B 5/06 Devices, other than using radiation, for detecting or locating foreign bodies for removing same A61B17/50 ; determining position of probes within or on the body of the patient
• CPC Class Codes: A61B 5/4381 Prostate evaluation or disorder diagnosis
• CPC Class Codes: A61K 49/00 Preparations for testing in vivo
• CPC Class Codes: A61K 49/0004 Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
• CPC Class Codes: G01R 33/1269 of molecules labeled with magnetic beads magnetic particles for bio assay G01N33/54326

Abstract

In a screening test method, and a device for implementing the screening test method, a diagnostic substance is provided that contains at least one biomarker connected with at least one ferromagnetic particle, the biomarker binding specifically to a target molecule that is formed by specific pathological prostrate tissue. The diagnostic substance is administered to the blood stream of a patient. A magnetometer is used to detect enrichment of the ferromagnetic particle in the prostrate, as an indicator of a level of the specific pathological prostrate tissue.

Claims

1. A screening test method to detect a prostate disease, comprising the steps of:

providing a diagnostic substance containing at least one biomarker connected with at least one ferromagnetic particle, said biomarker binding specifically to a target molecule that is formed by a specific pathological prostate tissue;

administering said diagnostic substance to the blood stream of a patient;

with a non-imaging magnetic sensor, measuring a level of enrichment of said ferromagnetic particles bound by said biomarker to said target molecule in the prostate of the patient by acquiring a first measurement value with said non-imaging magnetic sensor before said diagnostic substance reaches the prostate in the patient via said blood stream, and acquiring a second measurement value with said non-imaging magnetic sensor after measurement of a peak value occurring due to arrival of the diagnostic substance in the prostate of the subject has decayed to a substantially constant value; and

in a measurement apparatus supplied with the level of enrichment measured by said non-imaging magnetic sensor, automatically calculating a numerical level of said specific pathological prostate tissue in the patient by calculating a difference between said first measurement and said second measurement, and using said peak value as a third measurement value and calculating a difference between said third measurement value and said first measurement value, and using a quotient of the difference between said third measurement value and said first measurement value, and the difference between said first measurement value and said second measurement value, as said numerical level of pathological prostate tissue, and making said numerical level available in electronic form at an output of said measurement apparatus.

2. A screening test method as claimed in claim 1 comprising providing, as said biomarker, a biomarker that binds to a molecule that is present in the endothelium of a blood vessel of said pathological prostate tissue or the endothelium of a blood vessel adjacent thereto.

3. A screening test method as claimed in claim 1 comprising providing a biomarker as said biomarker, that binds to a molecule formed at an early stage of prostate cancer.

4. A screening test method as claimed in claim 3 comprising providing CEAMCAM-1 as said biomarker.

5. A screening test method as claimed in claim 1 comprising providing a biomarker, as said biomarker, that binds to a molecule formed in a stage of angiogenesis.

6. A screening test method as claimed in claim 5 comprising providing a biomarker that binds to VEGF as said biomarker that binds to a molecule formed in a stage of angiogenesis.

7. A screening test method as claimed in claim 6 comprising providing a biomarker that binds to alpha(v)-beta(3)-integrin as said biomarker that binds to a molecule formed in a stage of angiogenesis.

8. A screening test method as claimed in claim 7 comprising selecting said biomarker from the group consisting of antibodies, aptamers and anticalins.

9. A screening test method as claimed in claim 7 comprising employing a virus as said biomarker.

10. A screening test method as claimed in claim 9 comprising employing phage M13 as said virus.

11. A method as claimed in claim 7 comprising inserting said non-imaging magnetic sensor into the body of the patient via an intracorporeal probe.